CERIBELL INC
CBLLNASDAQTrading Snapshot
- Day Range
- $21.60 – $22.15
- 52-Week Range
- $10.85 – $24.33
- Volume
- $2.90B
- Avg Volume
- $2.86B
- Shares Outstanding
- 37.9M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $89M
- Last Q Revenue
- $28M
- P/E Ratio
- -12.1
- P/S Ratio
- 7.9x
- EPS (TTM)
- $-1.74
- Dividend Yield
- 0.00%
Why Investors Own CBLL
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CERIBELL INC
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $25 to $26.
BTIG Reiterates Buy on CeriBell, Maintains $28 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $28 price target.
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.
CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today